Gilead Sciences to Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27
FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov 12, 2018--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Robin L. Washington, Gilead’s Executive Vice President and Chief Financial Officer, and John McHutchison, AO, MD, Gilead’s Chief Scientific Officer and Head of Research & Development, will participate in a fireside chat at the Evercore ISI HealthCONx Conference in Boston on Tuesday, November 27 at 9:30 a.m. Eastern Time.
The audio portion of the fireside chat will be accessible live through the company’s Investors page at www.gilead.com/investors. Please connect to the company’s website at least 15 minutes prior to the start of the presentation to ensure adequate time for any software download that may be required to listen to the webcast. The replay will be available for 14 days following the presentation.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181112005782/en/
CONTACT: Gilead Sciences, Inc.
Sung Lee, 650-524-7792
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY HOSPITALS PHARMACEUTICAL RESEARCH SCIENCE
SOURCE: Gilead Sciences, Inc.
Copyright Business Wire 2018.
PUB: 11/12/2018 05:01 PM/DISC: 11/12/2018 05:01 PM